SGS Expands GMP-Compliant Solid State Analysis Services at it Lincolnshire, IL, US Facility
SGS Life Science Services has invested in X-Ray Powder Diffraction (XRPD) capabilities at its Lincolnshire, IL, laboratory for solid state analysis. The service, which has been fully qualified and validated, can now be offered to clients wishing to study crystallinity and polymorphism under cGMP conditions.
With this technique, the laboratory adds a comprehensive polymorph analysis, screening and determination service, complementing existing capabilities in Differential Scanning Calorimetry (DSC) and Thermo-Gravimetric Analysis (TGA). XRPD can also be used to identify crystalline materials, pursuant to USP <941> testing, as well as quantitative phase analysis and assessment of the degree of crystallinity of solids. The non-destructive nature of XRPD makes it suitable for systematic pre-formulation studies and for testing drug–excipient compatibility.
Installed and fully operational, the XRPD instrument is equipped with a very sensitive LynxeyeE detector which allows methods to be developed and optimized quickly without compromising data quality. Analysis under cGMP conditions is possible as the diffractogram is 21 CFR compliant.
“This investment is in response to growing client demand for extended solid-state characterization testing,” commented Mark Rogers, Senior VP, Life Science Services, SGS North America. “Adding XRPD to our global portfolio of services broadens the company’s expertize and widens our offering for both existing and potential new clients. The fact that we can offer this new service with full cGMP compliance is a key differentiator.”
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.